Insitro
Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics. In 2018, Daphne Koller established Insitro in South San Francisco, California..
Insitro
Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics. In 2018, Daphne Koller established Insitro in South San Francisco, California..
TL;DR
Founded: 2018
Founder & CEO: Daphne Koller
Headquarters: South San Francisco, CA
Focus: Machine-learning-driven drug discovery using high-throughput biology
Total disclosed funding: $643M (through 2021)
Company Overview
Problem Domain
Drug discovery and development; identifying targets and designing therapeutics using ML and high-throughput biology.
Founded
2018
Industry
Biotechnology / Drug discovery
Tech Stack
Funding Track Record
$400,000,000
Series C announced March 15, 2021; participation from multiple existing and new investors.
$100,000,000
Reported Series A announced in 2019.
Investor Signal
“Mix of life-science VCs, technology investors, and large institutional asset managers (including CPP Investments, Andreessen Horowitz, GV, Two Sigma, T. Rowe Price, BlackRock, ARCH Venture Partners, Third Rock Ventures, Foresite Capital, Casdin, Temasek, SoftBank Investment Advisors, Alexandria Venture Investments, HOF Capital).”